Across TCGA pan-cancer cohorts, MTHFD2P5 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MTHFD2P5’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MTHFD2P5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MTHFD2P5 is over-expressed in tumor.
KIRC, COAD, and BRCA are the cancer types where MTHFD2P5 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTHFD2P5 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.